Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma

被引：0
|
作者：
Lokhorst, Henk M.
Plesner, Torben
Gimsing, Peter
Nahi, Hareth
Minnema, Monique
Lassen, Ulrik Niels
Krejcik, Jakub
Laubach, Jacob
Lisby, Steen
Basse, Linda
Richardson, Paul Gerard Guy
机构：
[1] UMC Utrecht, Utrecht, Netherlands
[2] Vejle Hosp, Vejle, Denmark
[3] Copenhagen Univ Hosp, Copenhagen, Denmark
[4] Karolinska Univ, Sjukhuset Huddinge, Huddinge, Sweden
[5] Rigshosp, DK-2100 Copenhagen, Denmark
[6] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA
[7] Genmab AS, Copenhagen, Denmark
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8512
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
    Ghobrial, Irene M.
    Weller, Edie
    Vij, Ravi
    Munshi, Nikhil C.
    Banwait, Ranjit
    Bagshaw, Meghan
    Schlossman, Robert
    Leduc, Renee
    Chuma, Stacey
    Kunsman, Janet
    Laubach, Jacob
    Jakubowiak, Andrzej J.
    Maiso, Patricia
    Roccaro, Aldo
    Armand, Philippe
    Dollard, Akari
    Warren, Diane
    Harris, Brianna
    Poon, Tiffany
    Sam, Amy
    Rodig, Scott
    Anderson, Kenneth C.
    Richardson, Paul G.
    LANCET ONCOLOGY, 2011, 12 (03): : 263 - 272
  • [42] A PHASE I DOSE-ESCALATION STUDY OF PEGCRISANTASPASE ADMINISTERED BY INTRAVENOUS INFUSION IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGICAL MALIGNANCIES
    Salles, G.
    Lepretre, S.
    Le Gouill, S.
    Rigal-Huguet, F.
    Haioun, C.
    Balouet, S.
    Corn, T.
    Thomas, X.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S209 - S209
  • [43] Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer.
    Smit, WM
    Sufliarsky, J
    Spanik, S
    Wagnerová, M
    Kaye, S
    Oza, AM
    Gore, M
    Williams, K
    Johri, A
    Huinink, WWT
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 468S - 468S
  • [44] Daratumumab in Indian patients with relapsed and refractory multiple myeloma: a prospective, multicenter, phase IV study
    Kumar, Lalit
    Melinkeri, Sameer
    Ganesan, Prasanth
    Kumar, Jeevan
    Biswas, Ghanashyam
    Kilara, Nalini
    Pathalingappa, Harish
    Prasad, S. V. S. S.
    Jain, Minish
    Mishra, Sourav Kumar
    Prasad, Saurabh
    Boyella, Pavan Kumar
    Sahoo, Ranjit Kumar
    Bondarde, Shailesh
    Shah, Sandip
    Rege, Milind
    Deb, Uttiya
    Korde, Tanuja
    Dixit, Jitendra
    FUTURE ONCOLOGY, 2024, 20 (04) : 191 - 205
  • [45] A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma
    Shira Dinner
    Tamara J. Dunn
    Elizabeth Price
    Steven E. Coutré
    Jason Gotlib
    Caroline Berube
    Gregory P. Kaufman
    Bruno C. Medeiros
    Michaela Liedtke
    International Journal of Hematology, 2018, 108 : 267 - 273
  • [46] Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
    Berdeja, Jesus G.
    Hart, Lowell L.
    Mace, Joseph R.
    Arrowsmith, Edward R.
    Essell, James H.
    Owera, Rami S.
    Hainsworth, John D.
    Flinn, Ian W.
    HAEMATOLOGICA, 2015, 100 (05) : 670 - 676
  • [47] A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma
    Dinner, Shira
    Dunn, Tamara J.
    Price, Elizabeth
    Coutre, Steven E.
    Gotlib, Jason
    Berube, Caroline
    Kaufman, Gregory P.
    Medeiros, Bruno C.
    Liedtke, Michaela
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 108 (03) : 267 - 273
  • [48] A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
    Stakiw, Julie
    Kodad, Shruthi
    LeBlanc, Richard
    Sebag, Michael
    Hay, Annette E.
    Kukreti, Vishal
    Cote, Julie
    Camacho, Fernando
    Fu, Molei
    Gul, Engin
    Reece, Donna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (07): : 484 - 490
  • [49] A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts
    Nadeem, Omar
    Mo, Clifton C.
    Laubach, Jacob P.
    Bianchi, Giada
    Redd, Robert
    Barth, Peter
    Bayliss, Trevor J.
    Sanchorawala, Vaishali
    Shune, Leyla
    Distaso, Alexandra
    Dalton, Virginia
    Sperling, Adam S.
    Amweg, Laura
    McKenney, Mary
    Colson, Kathleen
    Millard, Ella L.
    Hou, Isabella
    Savell, Alexandra
    Masone, Kelly
    Munshi, Nikhil C.
    Ghobrial, Irene M.
    Anderson, Kenneth
    Richardson, Paul G.
    BLOOD, 2020, 136
  • [50] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew J.
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Bianchi, Giada
    O'Donnell, Elizabeth
    Branagan, Andrew R.
    Harrington, Cynthia C.
    Agyemang, Emerentia A.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette A.
    Bernstein, Zachary S.
    Lyons, Rebecca T.
    Riadi, Manal
    Rowell, Sean M.
    Mcvey, Cailin
    Goguen, Amy C.
    Horick, Nora K.
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345